BSE Live
Apr 20, 16:01Prev. Close
147.90
Open Price
150.65
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Apr 20, 15:58Prev. Close
148.01
Open Price
148.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
144.50 (1153)
| Balance Sheet of Sun Pharma Advanced Research Company (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | |
| 12 mths | 12 mths | 12 mths | ||
| EQUITIES AND LIABILITIES | ||||
| SHAREHOLDER'S FUNDS | ||||
| Equity Share Capital | 32.45 | 32.45 | 32.45 | |
| Total Share Capital | 32.45 | 32.45 | 32.45 | |
| Reserves and Surplus | -249.40 | 93.30 | 480.32 | |
| Total Reserves and Surplus | -249.40 | 93.30 | 480.32 | |
| Total Shareholders Funds | -216.95 | 125.76 | 512.78 | |
| Minority Interest | 0.00 | 0.00 | 0.00 | |
| NON-CURRENT LIABILITIES | ||||
| Long Term Borrowings | 100.00 | 0.00 | 0.00 | |
| Deferred Tax Liabilities [Net] | 0.00 | 0.00 | 0.00 | |
| Other Long Term Liabilities | 70.57 | 118.18 | 130.27 | |
| Long Term Provisions | 7.68 | 6.05 | 8.14 | |
| Total Non-Current Liabilities | 178.24 | 124.23 | 138.41 | |
| CURRENT LIABILITIES | ||||
| Short Term Borrowings | 158.19 | 47.00 | 0.05 | |
| Trade Payables | 113.92 | 142.29 | 148.25 | |
| Other Current Liabilities | 94.69 | 63.52 | 24.15 | |
| Short Term Provisions | 7.45 | 12.24 | 6.49 | |
| Total Current Liabilities | 374.24 | 265.06 | 178.95 | |
| Total Capital And Liabilities | 335.53 | 515.04 | 830.13 | |
| ASSETS | ||||
| NON-CURRENT ASSETS | ||||
| Tangible Assets | 98.69 | 107.35 | 105.41 | |
| Intangible Assets | 0.06 | 0.19 | 0.34 | |
| Capital Work-In-Progress | 0.56 | 1.27 | 1.87 | |
| Fixed Assets | 152.91 | 151.33 | 132.75 | |
| Non-Current Investments | 0.00 | 0.00 | 0.00 | |
| Deferred Tax Assets [Net] | 2.31 | 1.26 | 0.00 | |
| Long Term Loans And Advances | 0.00 | 0.00 | 0.00 | |
| Other Non-Current Assets | 154.12 | 93.07 | 242.41 | |
| Total Non-Current Assets | 309.34 | 245.66 | 375.16 | |
| CURRENT ASSETS | ||||
| Current Investments | 0.00 | 1.80 | 290.90 | |
| Inventories | 0.00 | 0.00 | 0.00 | |
| Trade Receivables | 16.06 | 15.53 | 32.71 | |
| Cash And Cash Equivalents | 1.96 | 155.33 | 111.58 | |
| Short Term Loans And Advances | 0.16 | 0.22 | 0.54 | |
| OtherCurrentAssets | 8.01 | 96.50 | 19.23 | |
| Total Current Assets | 26.20 | 269.39 | 454.96 | |
| Total Assets | 335.53 | 515.04 | 830.13 | |
| OTHER ADDITIONAL INFORMATION | ||||
| CONTINGENT LIABILITIES, COMMITMENTS | ||||
| Contingent Liabilities | 407.82 | 420.56 | 343.46 | |
| BONUS DETAILS | ||||
| Bonus Equity Share Capital | 0.00 | 0.00 | 0.00 | |
| NON-CURRENT INVESTMENTS | ||||
| Non-Current Investments Quoted Market Value | 0.00 | 0.00 | 0.00 | |
| Non-Current Investments Unquoted Book Value | 0.00 | 0.00 | 0.00 | |
| CURRENT INVESTMENTS | ||||
| Current Investments Quoted Market Value | 0.00 | 0.00 | 0.00 | |
| Current Investments Unquoted Book Value | 0.00 | 0.00 | 0.00 |
10.02.2026
Sun Pharma Adv Standalone December 2025 Net Sales at Rs 8.45 crore, down 43.33% Y-o-Y
10.02.2026
Sun Pharma Adv Consolidated December 2025 Net Sales at Rs 8.45 crore, down 43.33% Y-o-Y
16.01.2026
17.11.2025
Sun Pharma Adv Consolidated September 2025 Net Sales at Rs 7.86 crore, down 38.88% Y-o-Y
10.02.2026
Sun Pharma Adv Standalone December 2025 Net Sales at Rs 8.45 crore, down 43.33% Y-o-Y
10.02.2026
Sun Pharma Adv Consolidated December 2025 Net Sales at Rs 8.45 crore, down 43.33% Y-o-Y
17.11.2025
Sun Pharma Adv Consolidated September 2025 Net Sales at Rs 7.86 crore, down 38.88% Y-o-Y
12.11.2025
Sun Pharma Adv Standalone September 2025 Net Sales at Rs 7.86 crore, down 38.88% Y-o-Y
13.04.2026
13.04.2026
10.04.2026
09.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth